When Did Studies of Other Cysteamine Creams Measure Changes?

The published trials cited here ran 12 weeks, 16 weeks, or four months, with scheduled checkpoints along the way. In the 2015 melasma study, the first scheduled follow-up was at two months and showed a between-group difference. That study evaluated another 5% cream, not Illuminate Rx.

Those timelines came from other companies' creams, tested on other people. They're a useful frame. They aren't a promise.

The first scheduled follow-up in one melasma study was two months

The first scheduled follow-up in the 2015 study was at two months.

The 2015 study put 50 adults with melasma into two groups. Twenty-five used a 5% cysteamine cream at bedtime, 25 used a placebo. Pigment was tracked with a device that scores how much darker the patches are than the surrounding skin, so lower numbers mean the patch is closer to normal color.

At two months the gap was 39.7 with cysteamine against 63.8 with placebo. At four months: 26.2 against 60.7. Final melasma scores came in at 7.2 against 11.6.

One caveat. There was no checkpoint before two months, so whether anything changed earlier is unknown. One author was affiliated with Scientis Pharma.

Why do so many trials run four months?

In the two trials that measured at both an early and a late point, the later check showed more change.

A 2020 Brazilian trial followed 40 women. Melasma scores fell 24% at 60 days and 38% at 120 days in the cysteamine group. Hydroquinone did better in that trial, at 41% and 53%. Both groups also used a tinted sun protection factor (SPF) 50 sunscreen. One caveat on the design: people were sorted by a set method rather than pure chance, and only the scorers were kept unaware of who got what.

A 2020 trial of 50 people checked at two and four months. Cysteamine 5%, worn 15 minutes then washed off, was compared with a prescription combination cream worn overnight. The authors reported a greater modified Melasma Area and Severity Index reduction with 5% cysteamine than with the prescription combination.

A third trial used a 16-week endpoint with just 20 people, 14 of whom finished. Melasma scores fell about 21% with cysteamine and 32% with hydroquinone. The study did not detect a statistically significant between-group difference, and the small, uneven completer groups limit interpretation.

The linked abstracts for the melasma trials do not explain why those checkpoints were chosen. The hand-study full text says its 12-week duration was chosen after reviewing other treatment literature. The reported group means changed further by the final scheduled visit, and the cited studies do not report post-endpoint outcomes.

What changes a person's timeline

Timelines may differ by condition and body site, but these separate studies do not establish location as the cause.

A 2024 trial tested a stabilized cysteamine cream on sun spots on the backs of the hands. Thirty-three adults started, 30 finished. Everyone applied cream for 15 minutes daily, then rinsed, and both groups used moisturizer and SPF 50+ sunscreen.

At week 4, neither the subjective score nor the objective color measurement differed significantly between groups. At week 8, the subjective score differed but the objective measure did not. At week 12, both measures differed. Two cautions: the cysteamine group's spots started out significantly darker, and the cream tested was a branded product from Scientis.

The trials also differed in how long the cream stayed on, what strength it was, whether sunscreen came bundled in, and how many people took part. And every number above is a group average. A group average isn't a schedule for your face.

How do you track progress without fooling yourself?

The studies used devices and blinded scorers. You have a phone camera, which is fine if you use it consistently.

• Space your photos apart in time. The earliest scheduled checkpoint among the cited trials was week 4; that study first reported a between-group difference at week 8. Day-to-day comparisons mostly capture lighting noise.
• Same room, same light, same time of day, same angle, same distance.
• No filters, no makeup on the area.
• Compare across months, not days.

A photo can't confirm what a spot is. A new, changing, bleeding, or painful spot needs an in-person exam.

When irritation should change the plan

The package warning is the rule, not your patience.

The Illuminate Rx carton lists possible redness, dryness, skin irritation, and burning, and it says: if you suspect a possible allergy to the product, stop immediately and consult a doctor. Rinse your eyes with water if the cream gets in them. Don't use it if you're pregnant or breastfeeding.

For context, the Brazilian trial of a different 5% formula reported no severe reactions in either group, with redness and burning the most common complaints. That's group data. Irritation on your skin is a stop-and-ask signal, not something to push through for the sake of a timeline.

The limits

My search found no PubMed-indexed paper or ClinicalTrials.gov record through August 16, 2026 that names or tests Illuminate Rx, so every timeline above comes from another cream.

Those trials tested 5% where a strength was stated. Illuminate Rx is 10%. My search found no record through August 16, 2026 comparing the finished 10% formula with a 5% cream. A higher concentration does not prove greater benefit.

The trials were small: 20, 33, 40, and 50 people. One lost 6 of its 20. Results were mixed, with hydroquinone ahead in one trial and cysteamine ahead in another. These cited trials do not report post-endpoint outcomes after 12 weeks, 16 weeks, or four months.

FAQ

Next step

Read the linked studies to see the timelines in their own words, review the how-to-use page for the package directions, and take diagnosis questions to a board-certified dermatologist.